tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

AQST Stock Latest News

Aquestive Therapeutics Announces Key Legal Leadership Transition
Company AnnouncementsAquestive Therapeutics Announces Key Legal Leadership Transition
23h ago
8K
AQST
Aquestive chief legal officer, chief compliance officer Lori Braender steps down
PremiumThe Fly
Aquestive chief legal officer, chief compliance officer Lori Braender steps down
24h ago
AQST
Aquestive Therapeutics Faces Investor Lawsuit Over Alleged FDA Approval Misrepresentations for Anaphylm
PremiumClass Action
Aquestive Therapeutics Faces Investor Lawsuit Over Alleged FDA Approval Misrepresentations for Anaphylm
3d ago
AQST
Reiterating Buy on Aquestive: Near-Term Cost Pressures Offset by Anaphylm-Driven 2027 Growth Potential and $10 Target
PremiumRatings
Reiterating Buy on Aquestive: Near-Term Cost Pressures Offset by Anaphylm-Driven 2027 Growth Potential and $10 Target
12d ago
AQST
Aquestive Therapeutics Maps Risky Path to ANNAFILM Launch
PremiumCompany Announcements
Aquestive Therapeutics Maps Risky Path to ANNAFILM Launch
12d ago
AQST
AI Execution Risks Threaten Aquestive Therapeutics’ Competitiveness and Profitability
PremiumCompany AnnouncementsAI Execution Risks Threaten Aquestive Therapeutics’ Competitiveness and Profitability
15d ago
AQST
Aquestive Therapeutics price target lowered to $9 from $12 at Alliance Global
Premium
The Fly
Aquestive Therapeutics price target lowered to $9 from $12 at Alliance Global
16d ago
AQST
Aquestive Therapeutics Amends RTW Deal, Strengthens Financing Outlook
Premium
Company Announcements
Aquestive Therapeutics Amends RTW Deal, Strengthens Financing Outlook
17d ago
8K
AQST
Aquestive Therapeutics reports Q4 adjusted EPS (15c), consensus (12c)
PremiumThe Fly
Aquestive Therapeutics reports Q4 adjusted EPS (15c), consensus (12c)
17d ago
AQST
Aquestive Therapeutics sees FY26 revenue $46M-$50M, consensus $47.52M
PremiumThe Fly
Aquestive Therapeutics sees FY26 revenue $46M-$50M, consensus $47.52M
17d ago
AQST
Aquestive Therapeutics options imply 4.2% move in share price post-earnings
PremiumThe Fly
Aquestive Therapeutics options imply 4.2% move in share price post-earnings
17d ago
AQST
AQST Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
AQST Earnings Report this Week: Is It a Buy, Ahead of Earnings?
19d ago
AQST
Aquestive Highlights Strategy, Pipeline and Risk Disclosures
PremiumCompany AnnouncementsAquestive Highlights Strategy, Pipeline and Risk Disclosures
23d ago
8K
AQST
Aquestive announces poster presentations on Anaphylm at AAAAI meeting
Premium
The Fly
Aquestive announces poster presentations on Anaphylm at AAAAI meeting
29d ago
AQST
Aquestive Therapeutics: Strengthened Leadership and Regulatory Clarity Underpin Buy Rating on Anaphylm Opportunity
Premium
Ratings
Aquestive Therapeutics: Strengthened Leadership and Regulatory Clarity Underpin Buy Rating on Anaphylm Opportunity
1M ago
AQST
Aquestive Therapeutics appoints Greenhawt as Chief Medical Officer
PremiumThe Fly
Aquestive Therapeutics appoints Greenhawt as Chief Medical Officer
1M ago
AQST
Aquestive Therapeutics price target lowered to $6 from $8 at Lake Street
PremiumThe Fly
Aquestive Therapeutics price target lowered to $6 from $8 at Lake Street
2M ago
AQST
Reaffirming Buy on Anaphylm: Navigable FDA CRL, Limited Incremental Costs, and Intact 2027 Approval Timeline
PremiumRatings
Reaffirming Buy on Anaphylm: Navigable FDA CRL, Limited Incremental Costs, and Intact 2027 Approval Timeline
2M ago
AQST
Buy Rating Reaffirmed on Aquestive Therapeutics as Operational FDA Setbacks De-Risk Anaphylm’s Path to Approval
PremiumRatings
Buy Rating Reaffirmed on Aquestive Therapeutics as Operational FDA Setbacks De-Risk Anaphylm’s Path to Approval
2M ago
AQST
Alliance Global sees Aquestive’s Anaphylm CRL as fixable, reiterates Buy rating
PremiumThe FlyAlliance Global sees Aquestive’s Anaphylm CRL as fixable, reiterates Buy rating
2M ago
AQST
Buy Rating Maintained on Aquestive Therapeutics as FDA CRL Seen as Operational Setback with Manageable Risk and Attractive Long‑Term Risk‑Reward
Premium
Ratings
Buy Rating Maintained on Aquestive Therapeutics as FDA CRL Seen as Operational Setback with Manageable Risk and Attractive Long‑Term Risk‑Reward
2M ago
AQST
Leerink sees ‘silver lining’ in Aquestive CRL given defined path to approval
Premium
The Fly
Leerink sees ‘silver lining’ in Aquestive CRL given defined path to approval
2M ago
AQST

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >